283 related articles for article (PubMed ID: 25300593)
1. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.
Castiglia P
Adv Ther; 2014 Oct; 31(10):1011-44. PubMed ID: 25300593
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
3. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
[TBL] [Abstract][Full Text] [Related]
5. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
6. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
[TBL] [Abstract][Full Text] [Related]
7. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
Savulescu C; Krizova P; Lepoutre A; Mereckiene J; Vestrheim DF; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Varon E; Cotter S; Winje BA; Munoz-Almagro C; Garcia L; Castilla J; Smith A; Henriques-Normark B; Celentano LP; Hanquet G;
Lancet Respir Med; 2017 Aug; 5(8):648-656. PubMed ID: 28359798
[TBL] [Abstract][Full Text] [Related]
8. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
[TBL] [Abstract][Full Text] [Related]
9. Streptococcus pneumoniae serotype distribution in Vojvodina before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.
Petrović V; Šeguljev Z; Ristić M; Djekić-Malbaša J; Radosavljević B; Medić D; Mihajlović-Ukropina M; Hadnadjev M; Gajic I; Opavski N
Srp Arh Celok Lek; 2016; 144(9-10):521-6. PubMed ID: 29653038
[TBL] [Abstract][Full Text] [Related]
10. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
Tin Tin Htar M; van Den Biggelaar AHJ; Sings H; Ferreira G; Moffatt M; Hall-Murray C; Verstraeten T; Gessner BD; Schmitt HJ; Jodar L
Expert Rev Vaccines; 2019 Oct; 18(10):1069-1089. PubMed ID: 31585049
[No Abstract] [Full Text] [Related]
11. Impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 5 years of age in the Czech Republic.
Kozakova J; Krizova P; Maly M
PLoS One; 2021; 16(2):e0247862. PubMed ID: 33635933
[TBL] [Abstract][Full Text] [Related]
12. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.
Hanquet G; Krizova P; Valentiner-Branth P; Ladhani SN; Nuorti JP; Lepoutre A; Mereckiene J; Knol M; Winje BA; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Slotved HC; Fry NK; Rinta-Kokko H; Varon E; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Latasa P; Castilla J; Smith A; Henriques-Normark B; Whittaker R; Pastore Celentano L; Savulescu C;
Thorax; 2019 May; 74(5):473-482. PubMed ID: 30355641
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
[TBL] [Abstract][Full Text] [Related]
14. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
15. Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13.
Løvlie A; Vestrheim DF; Aaberge IS; Steens A
BMC Infect Dis; 2020 Jan; 20(1):29. PubMed ID: 31924177
[TBL] [Abstract][Full Text] [Related]
16. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
Wijayasri S; Hillier K; Lim GH; Harris TM; Wilson SE; Deeks SL
PLoS One; 2019; 14(12):e0226353. PubMed ID: 31834926
[TBL] [Abstract][Full Text] [Related]
17. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
[TBL] [Abstract][Full Text] [Related]
18. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe.
Bonnave C; Mertens D; Peetermans W; Cobbaert K; Ghesquiere B; Deschodt M; Flamaing J
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):785-791. PubMed ID: 30778705
[TBL] [Abstract][Full Text] [Related]
19. Modeling Possible Inclusion of Pneumococcal Conjugate Vaccine into the National Immunization Program for Infants in India.
Ghia C; Wasserman M; Fletcher M; Farkouh R; Rambhad G
Value Health Reg Issues; 2018 May; 15():99-105. PubMed ID: 29655052
[TBL] [Abstract][Full Text] [Related]
20. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice.
Azzari C; Martinón-Torres F; Schmitt HJ; Dagan R
Pediatr Infect Dis J; 2014 Aug; 33(8):858-64. PubMed ID: 24618937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
